(Q41096806)

26 September 2017

1 reference

title

Immunotherapy and gene transfer in the treatment of the oncology patient: role of transfusion medicine (English)

1 reference

26 September 2017

1 reference

Hillyer CD

1

1 reference

PubMed ID

8787926

26 September 2017

Klein HG

series ordinal

2

1 reference

26 September 2017

1 January 1996

1 reference

Transfusion Medicine Reviews

26 September 2017

1 reference

26 September 2017

10

1 reference

26 September 2017

1

1 reference

26 September 2017

1-14

1 reference

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia

26 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Human gene therapy comes of age.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Alternative sources of hematopoietic stem cells for bone marrow transplantation and rescue

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Bone marrow and peripheral blood stem cell harvesting

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

How does bone-marrow transplantation cure leukaemia?

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Collection and use of stem cells; role of transfusion centers in bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Cellular and Humoral immunity to Different Types of Human Neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Tube leukocyte (monocyte) adherence inhibition assay for the detection of anti-tumour immunity. III. "Blockade" of monocyte reactivity by excess free antigen and immune complexes in advanced cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Antibodies and antigen expression in human melanoma detected by the immune adherence test

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Problems Associated With Study of Cell-Mediated Immunity to Human Tumors by Microcytotoxicity Assays

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Active immunotherapy for acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Spontaneous regression of human melanoma: clinical and experimental studies

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Serotherapy of malignant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

A perspective of monoclonal antibodies: past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Human monoclonal antibodies: prospects for the therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Future role of radiolabeled monoclonal antibodies in oncological diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

The clinical significance of interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Adoptive cellular therapy of malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

A new regimen of interleukin 2 and lymphokine-activated killer cells. Efficacy without significant toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Adoptive immunotherapy with autologous macrophages: current status and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Adoptive immunotherapy: novel applications of blood cell separators

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Ex vivo activation and retransfusion of white blood cells. The immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

An improved method for the generation of human lymphokine activated killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Adoptive immunotherapy with peripheral blood lymphocytes cocultured in vitro with autologous tumor cells and interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Adoptive chemoimmunotherapy for the treatment of relapsed and refractory solid tumors using ex vivo activated memory T cells (autolymphocyte therapy) and cyclophosphamide.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Murine interleukin-4 displays potent anti-tumor activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

The basic science of gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Cellular gene therapy: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Lymphocyte gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

The development of gene therapy for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Gene therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Use of suicide genes in gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Gene therapy: current status and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Modulation of oncogene and tumor-suppressor gene expression: a novel strategy for cancer prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Retroviral-mediated transduction of p53 gene increases TGF-beta expression in a human glioblastoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Endogenous stem cell repopulation resulting in mixed hematopoietic chimerism following total body irradiation and marrow transplantation for acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Collection and use of circulating hematopoietic progenitor cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

Methods for the reduction of transfusion-transmitted cytomegalovirus infection: filtration versus the use of seronegative donor units

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980118-0

7 January 2021

10.1016/S0887-7963(96)80118-0

Identifiers

DOI

1 reference

26 September 2017

1 reference

PubMed ID

8787926